RxDoctor Payments Data

David Rosenthal, MD

Radiation Oncology · Houston, TXNPI 1669565719

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $35,245 of the $40,357 with a category attached, or 87.3%. Merck accounts for 92.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $13,583 and has fallen 97.4% since, to $357 in 2023. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,357in general payments, 2019–2025

Across 39 payments — averaging $1034.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$37K
  • Eisai Inc.$3K
  • EMD Serono, Inc.$357

What the payments were for

  • Consulting fees$35,24587%
  • Travel & lodging$4,13810%
  • Food & beverage$9742%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck34$37,466
Eisai Inc.1$2,535
EMD Serono, Inc.4$357

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,357 in reported general payments places this provider in the 95th percentile of 418 radiation oncology providers in Texas.

See all radiation oncology providers in Texas

Medicare billing

Part B allowed, 2024
$102,600
Medicare patients
274
Services billed
1,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →